Genfit Dirección

Dirección controles de criterios 4/4

El CEO de Genfit es M. Prigent , nombrado en Sep 2019, tiene una permanencia de 5.17 años. compensación anual total es €664.22K, compuesta por 59.3% salario y 40.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.062% de las acciones de la empresa, por valor de €124.68K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 7.4 años, respectivamente.

Información clave

M. Prigent

Chief Executive Officer (CEO)

€664.2k

Compensación total

Porcentaje del salario del CEO	59.3%
Permanencia del CEO	5.2yrs
Participación del CEO	0.06%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de M. Prigent en comparación con los beneficios de Genfit?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	€22m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

Compensación vs. Mercado: La compensación total ($USD691.68K) de M. está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD782.05K).

Compensación vs. Ingresos: La compensación de M. ha sido consistente con los resultados de la empresa en el último año.

CEO

M. Prigent (55 yo)

5.2yrs

Permanencia

€664,224

Compensación

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.093% € 189.2k
M. Prigent	Chief Executive Officer	5.2yrs	€664.22k	0.062% € 124.7k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	sin datos	sin datos
Thomas Baetz	Chief Financial Officer	3.6yrs	sin datos	sin datos
Pascal Caisey	Chief Operating Officer	2.7yrs	sin datos	0.0095% € 19.2k
Meriam Kabbaj	Chief Technology Officer	1.9yrs	sin datos	sin datos
Dean Hum	Chief Scientific Officer	2.8yrs	€795.03k	0.021% € 41.8k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.7yrs	sin datos	0.0094% € 19.0k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.8yrs	sin datos	0.023% € 45.6k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.7yrs	sin datos	0.0055% € 11.2k
Emilie Desodt	Executive Vice President of Human Resources	2.7yrs	sin datos	0.0035% € 7.1k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.6yrs	sin datos	sin datos

2.8yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de XUP se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.093% € 189.2k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	sin datos	sin datos
Philippe Moons	Board Observer	3.8yrs	€7.63k	0.0021% € 4.2k
Florence Séjourné	Director	7.4yrs	sin datos	sin datos
Scott L. Friedman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Arun Sanyal	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Trauner	Member of Scientific Advisory Board	no data	sin datos	sin datos
Catherine Larue	Independent Director	7.4yrs	€43.60k	sin datos
Vlad Ratziu	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anne-Helene Monsellato	Independent Director	7.4yrs	€39.24k	sin datos
Katherine Kalin	Independent Director	4.3yrs	€39.24k	0.010% € 20.3k
Eric Baclet	Independent Vice-Chairman of the Board	4.3yrs	€47.96k	0.0024% € 4.9k

7.4yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de XUP se considera experimentada (7.4 años de antigüedad promedio).

Genfit Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 20%

First half 2024 earnings released: EPS: €0.61 (vs €0.42 loss in 1H 2023)

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

New minor risk - Share price stability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: €5.19

Genfit SA, Annual General Meeting, May 28, 2021

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.75

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.59

New 90-day low - €3.99

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad